Nucleic acid drugs in the clinic

Bibliography

• ZAMECNIK PC, STEPHENSON ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA (1978) 75(1):280-284.
   Google Scholar
• ECKSTEIN F: Phosphorothioate oligodeoxynucleotides:what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev. (2000) 10(2):117-121.
   PubMedGoogle Scholar
• STEIN D, FOSTER E, HUANG SB, WELLER D, SUMMERTON J: A specificity comparison of four antisense types: morpholino, 2'-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. (1997) 7(3):151-157.
   PubMedGoogle Scholar
• HAMPEL A: The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy. Prog. Nucleic. Acid Res. Mol. Biol. (1998) 58:1-39.
   Web of Science ®Google Scholar
• BREAKER RR, JOYCE GF: A DNA enzyme that cleaves RNA. Chem. Biol. (1994) 1(4):223-229.
   PubMedGoogle Scholar
• COGONI C, MACINO G: Gene silencing in Neurospora crassa requires a protein homologous to RNA-dependent RNA polymerase. Nature (1999) 399(6732):166-169.
   PubMed Web of Science ®Google Scholar
• FIRE A, XU S, MONTGOMERY MK, KOSTAS SA, DRIVER SE, MELLO CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391(6669):806-811.
   PubMed Web of Science ®Google Scholar
• CARTHEW RW: Gene silencing by double-stranded RNA. Curr. Opin. Cell Biol. (2001) 13(2):244-248.
   Web of Science ®Google Scholar
• ELBASHIR SM, HARBORTH J, LENDECKEL W, YALCIN A, WEBER K, TUSCHL T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411(6836):494-498.
   PubMed Web of Science ®Google Scholar
• MATZKE M, MATZKE AJ: Plants, RNAi, and the Nobel Prize. Science (2006) 314(5803):1242-1243.
   PubMedGoogle Scholar
• KURRECK J: siRNA efficiency: structure or sequence – that is the question. J. Biomed. Biotechnol. (2006) 2006(4):83757.
   Google Scholar
• KADOTANI N, NAKAYASHIKI H, TOSA Y, MAYAMA S: One of the two dicer-like proteins in the filamentous fungi Magnaporthe oryzae genome is responsible for hairpin RNA-triggered RNA silencing and related small interfering RNA accumulation. J. Biol. Chem. (2004) 279(43):44467-44474.
   Google Scholar
• ELBASHIR SM, MARTINEZ J, PATKANIOWSKA A, LENDECKEL W, TUSCHL T: Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo. J. (2001) 20(23):6877-6888.
   PubMed Web of Science ®Google Scholar
• ZAMORE PD, TUSCHL T, SHARP PA, BARTEL DP: RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell (2000) 101(1):25-33.
   PubMed Web of Science ®Google Scholar
• ROBALINO J, BARTLETT T, SHEPARD E et al.: Double-stranded RNA induces sequence-specific antiviral silencing in addition to nonspecific immunity in a marine shrimp:convergence of RNA interference and innate immunity in the invertebrate antiviral response? J. Virol. (2005) 79(21):13561-13571.
   Google Scholar
• ROMANO PR, MCCALLUS DE, PACHUK CJ: RNA interference-mediated prevention and therapy for hepatocellular carcinoma. Oncogene (2006) 25(27):3857-3865.
   PubMed Web of Science ®Google Scholar
• LIMA WF, MONIA BP, ECKER DJ, FREIER SM: Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry (1992) 31(48):12055-12061.
   PubMed Web of Science ®Google Scholar
• GIFFORD LK, OPALINSKA JB, JORDAN D et al.: Identification of antisense nucleic acid hybridization sites in mRNA molecules with self-quenching fluorescent reporter molecules. Nucleic Acids Res. (2005) 33(3):e28.
   PubMedGoogle Scholar
• OPALINSKA JB, KALOTA A, GIFFORD LK et al.: Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules. Nucleic Acids Res (2004) 32(19):5791-5799.
   PubMed Web of Science ®Google Scholar
• O'BRIEN SM, CUNNINGHAM CC, GOLENKOV AK, TURKINA AG, NOVICK SC, RAI KR: Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J. Clin. Oncol. (2005) 23(30):7697-7702.
   Google Scholar
• ADVANI R, LUM BL, FISHER GA et al.: A Phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Invest New Drugs (2005) 23(5):467-477.
   PubMed Web of Science ®Google Scholar
• CHI KN, EISENHAUER E, FAZLI L et al.: A Phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. (2005) 97(17):1287-1296.
   Google Scholar
• SCACHERI PC, ROZENBLATT-ROSEN O, CAPLEN NJ et al.: Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. USA (2004) 101(7):1892-1897.
   Google Scholar
• GRIMM D, STREETZ KL, JOPLING CL et al.: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 441(7092):537-541.
   PubMed Web of Science ®Google Scholar
• BRIDGE AJ, PEBERNARD S, DUCRAUX A, NICOULAZ AL, IGGO R: Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. (2003) 34(3):263-264.
   PubMed Web of Science ®Google Scholar
• SAXENA S, JONSSON ZO, DUTTA A: Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J. Biol. Chem. (2003) 278(45):44312-44319.
   Google Scholar
• JACKSON AL, BARTZ SR, SCHELTER J et al.: Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 21(6):635-637.
   Google Scholar
• DOENCH JG, PETERSEN CP, SHARP PA: siRNAs can function as miRNAs. Genes Dev. (2003) 17(4):438-442.
   PubMed Web of Science ®Google Scholar
• DYKXHOORN DM, PALLISER D, LIEBERMAN J: The silent treatment: siRNAs as small molecule drugs. Gene Ther. (2006) 13(6):541-552.
   Web of Science ®Google Scholar
• FEDOROV Y, KING A, ANDERSON E et al.: Different delivery methods-different expression profiles. Nat. Methods (2005) 2(4):241.
   PubMedGoogle Scholar
• BONHAM MA, BROWN S, BOYD A et al.: An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Res. (1995) 23(7):1197-1203.
   PubMed Web of Science ®Google Scholar
• GEE JE, ROBBINS I, VAN DER LAAN AC et al.: Assessment of high-affinity hybridization, RNase H cleavage, and covalent linkage in translation arrest by antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. (1998) 8(2):103-111.
   PubMedGoogle Scholar
• NIELSEN PE: Antisense properties of peptide nucleic acid. Methods Enzymol. (2000) 313:156-164.
   Web of Science ®Google Scholar
• SUMMERTON J, WELLER D: Morpholino antisense oligomers:design, preparation, and properties. Antisense Nucleic Acid Drug Dev. (1997) 7(3):187-195.
   PubMed Web of Science ®Google Scholar
• DEVI GR, BEER TM, CORLESS CL, ARORA V, WELLER DL, IVERSEN PL: In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin. Cancer Res. (2005) 11(10):3930-3938.
   Google Scholar
• IVERSEN PL: Phosphorodiamidate morpholino oligomers:favorable properties for sequence-specific gene inactivation. Curr. Opin. Mol. Ther. (2001) 3(3):235-238.
   Web of Science ®Google Scholar
• KALOTA A, KARABON L, SWIDER CR et al.: 2'-deoxy-2'-fluoro-β-d-arabinonucleic acid (2'F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing. Nucleic Acids Res (2006) 34(2):451-461.
   PubMed Web of Science ®Google Scholar
• PRADEEPKUMAR PI, AMIRKHANOV NV, CHATTOPADHYAYA J: Antisense oligonuclotides with oxetane-constrained cytidine enhance heteroduplex stability, and elicit satisfactory RNase H response as well as showing improved resistance to both exo and endonucleases. Org. Biomol. Chem. (2003) 1(1):81-92.
   Google Scholar
• CZAUDERNA F, FECHTNER M, DAMES S et al.: Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. (2003) 31(11):2705-2716.
   PubMed Web of Science ®Google Scholar
• HARBORTH J, ELBASHIR SM, VANDENBURGH K et al.: Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. (2003) 13(2):83-105.
   PubMed Web of Science ®Google Scholar
• ELMEN J, THONBERG H, LJUNGBERG K et al.: Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. (2005) 33(1):439-447.
   PubMed Web of Science ®Google Scholar
• YAKUBOV LA, DEEVA EA, ZARYTOVA VF et al.: Mechanism of oligonucleotide uptake by cells:involvement of specific receptors? Proc. Natl. Acad. Sci. USA (1989) 86(17):6454-6458.
   Google Scholar
• GOKHALE PC, ZHANG C, NEWSOME JT et al.: Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin. Cancer Res. (2002) 8(11):3611-3621.
   Google Scholar
• RUDIN CM, MARSHALL JL, HUANG CH et al.: Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a Phase I study. Clin. Cancer Res. (2004) 10(21):7244-7251.
   Google Scholar
• DRITSCHILO A, HUANG CH, RUDIN CM et al.: Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin. Cancer Res. (2006) 12(4):1251-1259.
   Google Scholar
• BRUMMELKAMP TR, BERNARDS R, AGAMI R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 2(3):243-247.
   PubMed Web of Science ®Google Scholar
• SUMIMOTO H, MIYAGISHI M, MIYOSHI H et al.: Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene (2004) 23(36):6031-6039.
   PubMed Web of Science ®Google Scholar
• REICHERT J, GRASNICK D, AFONIN S, BUERCK J, WADHWANI P, ULRICH AS: A critical evaluation of the conformational requirements of fusogenic peptides in membranes. Eur. Biophys. J. (2006).
   Google Scholar
• SHANKAR P, MANJUNATH N, LIEBERMAN J: The prospect of silencing disease using RNA interference. Jama (2005) 293(11):1367-1373.
   PubMed Web of Science ®Google Scholar
• ZIMMERMANN TS, LEE AC, AKINC A et al.: RNAi-mediated gene silencing in non-human primates. Nature (2006) 441(7089):111-114.
   PubMed Web of Science ®Google Scholar
• ORR RM: Technology evaluation:fomivirsen, Isis Pharmaceuticals Inc/CIBA vision. Curr. Opin. Mol. Ther. (2001) 3(3):288-294.
   Web of Science ®Google Scholar
• BANERJEE D: Genasense (Genta Inc). Curr. Opin. Investig. Drugs (2001) 2(4):574-580.
   Google Scholar
• BEDIKIAN AY, MILLWARD M, PEHAMBERGER H et al.: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma the oblimersen melanoma study group. J. Clin. Oncol. (2006) 24(29):4738-4745.
   Google Scholar
• CASTRO JE, PRADA CE, AGUILLON RA et al.: Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. Leukemia (2006) 20(4):680-688.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, HOLMLUND JT, KRAYNAK M et al.: Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-α, in patients with advanced cancer. J. Clin. Oncol. (1999) 17(11):3586-3595.
   Google Scholar
• WINKLER U, JENSEN M, MANZKE O, SCHULZ H, DIEHL V, ENGERT A: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood (1999) 94(7):2217-2224.
   PubMed Web of Science ®Google Scholar
• MCHUTCHISON JG, PATEL K, POCKROS P et al.: A Phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J. Hepatol. (2006) 44(1):88-96.
   Google Scholar
• WINQUIST E, KNOX J, AYOUB JP et al.: Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma. A National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest. New Drugs (2006) 24(2):159-167.
   PubMed Web of Science ®Google Scholar
• PAZ-ARES L, DOUILLARD JY, KORALEWSKI P et al.: Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-α antisense oligonucleotide, in patients with advanced-stage non--small-cell lung cancer. J. Clin. Oncol. (2006) 24(9):1428-1434.
   Google Scholar
• WENG DE, MASCI PA, RADKA SF et al.: A Phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol. Cancer Ther. (2005) 4(6):948-955.
   Web of Science ®Google Scholar
• VOLLMER J, WEERATNA R, PAYETTE P et al.: Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. (2004) 34(1):251-262.
   Google Scholar
• HEMMI H, KAISHO T, TAKEDA K, AKIRA S: The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J. Immunol. (2003) 170(6):3059-3064.
   Google Scholar
• KRIEG AM: Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. (2006) 5(6):471-484.
   PubMed Web of Science ®Google Scholar
• TUERK C, GOLD L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) (249)(4968):505-510.
   PubMed Web of Science ®Google Scholar
• MALLIKARATCHY P, STAHELIN RV, CAO Z, CHO W, TAN W: Selection of DNA ligands for protein kinase C-δ. Chem. Commun. (Camb) (2006) 30:3229-3231.
   Google Scholar
• LEE JH, CANNY MD, DE ERKENEZ A, et al.: A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc. Natl. Acad. Sci. USA (2005) 102(52):18902-18907.
   Google Scholar
• GRAGOUDAS ES, ADAMIS AP, CUNNINGHAM ET, Jr., FEINSOD M, GUYER DR: Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. (2004) 351(27):2805-2816.
   Google Scholar
• RUSCONI CP, SCARDINO E, LAYZER J et al.: RNA aptamers as reversible antagonists of coagulation factor IXa. Nature (2002) 419(6902):90-94.
   PubMed Web of Science ®Google Scholar
• BOOMER RM, LEWIS SD, HEALY JM, KURZ M, WILSON C, MCCAULEY TG: Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues. Oligonucleotides (2005) 15(3):183-195.
   PubMed Web of Science ®Google Scholar
• WILLIS MC, COLLINS BD, ZHANG T et al.: Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug. Chem. (1998) 9(5):573-582.
   Google Scholar
• DOUGAN H, LYSTER DM, VO CV, STAFFORD A, WEITZ JI, HOBBS JB: Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl. Med. Biol. (2000) 27(3):289-297.
   Google Scholar
• DESAI AA, SCHILSKY RL, YOUNG A et al.: A Phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann. Oncol. (2005) 16(6):958-965.
   Google Scholar
• MARCUCCI G, STOCK W, DAI G et al.: Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia:pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol. (2005) 23(15):3404-3411.
   Google Scholar
• WESTERHOUT EM, OOMS M, VINK M, DAS AT, BERKHOUT B: HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res. (2005) 33(2):796-804.
   PubMed Web of Science ®Google Scholar
• CHIU YL, RANA TM: RNAi in human cells:basic structural and functional features of small interfering RNA. Mol. Cell (2002) 10(3):549-561.
   PubMed Web of Science ®Google Scholar